Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists
出版年份 2019 全文链接
标题
Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists
作者
关键词
-
出版物
Cancers
Volume 11, Issue 7, Pages 1014
出版商
MDPI AG
发表日期
2019-07-22
DOI
10.3390/cancers11071014
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Rucaparib: A Review in Ovarian Cancer
- (2019) Matt Shirley Targeted Oncology
- A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
- (2019) Lukasz Skalniak et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Comparison of genotoxic versus nongenotoxic stabilization of p53 provides insight into parallel stress-responsive transcriptional networks
- (2019) Allison N. Catizone et al. CELL CYCLE
- Divergent Dynamics and Functions of ERK MAP Kinase Signaling in Development, Homeostasis and Cancer: Lessons from Fluorescent Bioimaging
- (2019) Yu Muta et al. Cancers
- Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding
- (2019) Saif Zaman et al. MOLECULAR CANCER THERAPEUTICS
- Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
- (2018) Markella Konstantinidou et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- A tale of two antibodies: obinutuzumab versus rituximab
- (2018) Ciara L. Freeman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non–muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients
- (2018) Judith Bosschieter et al. EUROPEAN UROLOGY
- MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
- (2018) Katja Seipel et al. HAEMATOLOGICA
- A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma
- (2018) Hanjie Yi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression
- (2018) Noah Isakov SEMINARS IN CANCER BIOLOGY
- Tolerability of obinutuzumab therapy in patients with rituximab-relapsed/refractory B-cell malignancies - a retrospective single center cohort study
- (2018) Theo Pirich et al. Oncotarget
- MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
- (2018) Katja Seipel et al. HAEMATOLOGICA
- Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
- (2018) Carlos Cuesta-Mateos et al. Frontiers in Immunology
- Zinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer Therapeutics
- (2018) Samuel Kogan et al. Cancers
- Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations
- (2018) Edwige Kasper et al. EUROPEAN JOURNAL OF CANCER
- Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
- (2018) Björn Stolte et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CDK4 inhibition diminishes p53 activation by MDM2 antagonists
- (2018) Anusha Sriraman et al. Cell Death & Disease
- Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors
- (2018) Hongsai Chen et al. EBioMedicine
- Apoptosis and apoptotic body: disease message and therapeutic target potentials
- (2018) Xuebo Xu et al. BIOSCIENCE REPORTS
- A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours
- (2018) Vincent A. de Weger et al. BRITISH JOURNAL OF CANCER
- The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway
- (2018) Yong Guo et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma
- (2018) Lindi Chen et al. INTERNATIONAL JOURNAL OF CANCER
- Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
- (2018) Lukasz Skalniak et al. Cancers
- ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma
- (2018) Chiao-En Wu et al. Cancers
- Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
- (2017) Audrey Laroche-Clary et al. Journal of Hematology & Oncology
- MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
- (2017) Veronica Tisato et al. Journal of Hematology & Oncology
- Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development
- (2017) Angelo Aguilar et al. JOURNAL OF MEDICINAL CHEMISTRY
- WIP1 phosphatase as pharmacological target in cancer therapy
- (2017) Soňa Pecháčková et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Protein kinase C in cancer: The top five unanswered questions
- (2017) Mariana Cooke et al. MOLECULAR CARCINOGENESIS
- Reviving the guardian of the genome: Small molecule activators of p53
- (2017) Daniel Nguyen et al. PHARMACOLOGY & THERAPEUTICS
- Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf−/−mouse model
- (2017) Emilie A. Chapeau et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oridonin synergizes with Nutlin-3 in osteosarcoma cells by modulating the levels of multiple Bcl-2 family proteins
- (2017) Xiao-Hui Wang et al. TUMOR BIOLOGY
- Metformin and cancer: An existing drug for cancer prevention and therapy (Review)
- (2017) Fuming Zi et al. Oncology Letters
- Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
- (2017) Maryam Zanjirband et al. Oncotarget
- Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
- (2017) Loredana Urso et al. Oncotarget
- Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma
- (2017) Viktor Arnhold et al. Oncotarget
- MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas
- (2017) Audrey Laroche et al. Oncotarget
- Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma
- (2017) Alan Van Goethem et al. Oncotarget
- Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models
- (2017) Hui Qin Wang et al. eLife
- The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
- (2016) Andreas C. Joerger et al. Annual Review of Biochemistry
- Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument
- (2016) Pascal Furet et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Inhibitors of histone deacetylase as antitumor agents: A critical review
- (2016) Mohammed Manal et al. BIOORGANIC CHEMISTRY
- Onto better TRAILs for cancer treatment
- (2016) D de Miguel et al. CELL DEATH AND DIFFERENTIATION
- Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388)
- (2016) Frank Herting et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses
- (2016) Prithviraj Bose et al. Expert Opinion on Drug Metabolism & Toxicology
- Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
- (2016) Christian Lehmann et al. Journal of Hematology & Oncology
- MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition
- (2016) Lina S. Schneider et al. Molecular Oncology
- Combine and conquer: challenges for targeted therapy combinations in early phase trials
- (2016) Juanita S. Lopez et al. Nature Reviews Clinical Oncology
- The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1
- (2016) Clemens Reuther et al. NEUROENDOCRINOLOGY
- Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis
- (2016) Xiu Fen Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
- (2016) Joonil Jung et al. Nature Communications
- TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation
- (2016) Catherine J. Drummond et al. Oncotarget
- Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients
- (2016) Stefania Trino et al. Oncotarget
- Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity
- (2016) Anusha Sriraman et al. Oncotarget
- Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia
- (2016) Rebecca Voltan et al. Oncotarget
- Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma
- (2016) Guillaume Carita et al. Oncotarget
- Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer
- (2016) Maryam Zanjirband et al. Oncotarget
- V-ATPase inhibition increases cancer cell stiffness and blocks membrane related Ras signaling - a new option for HCC therapy
- (2016) Karin Bartel et al. Oncotarget
- The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
- (2016) Jiandong Chen Cold Spring Harbor Perspectives in Medicine
- Feedbacks, Bifurcations, and Cell Fate Decision-Making in the p53 System
- (2016) Beata Hat et al. PLoS Computational Biology
- Oridonin induces apoptosis in uveal melanoma cells by upregulation of Bim and downregulation of Fatty Acid Synthase
- (2015) Zhimin Gu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
- (2015) Concepción Sánchez-Martínez et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas
- (2015) Antònia Obrador-Hevia et al. CANCER INVESTIGATION
- Actinomycin D and nutlin-3a synergistically promote phosphorylation of p53 on serine 46 in cancer cell lines of different origin
- (2015) Artur Zajkowicz et al. CELLULAR SIGNALLING
- How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures
- (2015) Natalia Estrada-Ortiz et al. ChemMedChem
- Effective Targeting of the P53-MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia
- (2015) J. Richmond et al. CLINICAL CANCER RESEARCH
- Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
- (2015) C. G. Hoffman-Luca et al. CLINICAL CANCER RESEARCH
- The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy
- (2015) Zutao Yu et al. Future Medicinal Chemistry
- Antibody-based immunotherapy of solid cancers: progress and possibilities
- (2015) Christopher F Nicodemus Immunotherapy
- ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
- (2015) Shundong Cang et al. Journal of Hematology & Oncology
- Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors
- (2015) Philipp Holzer et al. JOURNAL OF MEDICINAL CHEMISTRY
- PARP inhibitors: A new era of targeted therapy
- (2015) Shifalika Tangutoori et al. MATURITAS
- Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells
- (2015) A. M. Carrillo et al. MOLECULAR CANCER RESEARCH
- Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
- (2015) E. Weisberg et al. MOLECULAR CANCER THERAPEUTICS
- Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model
- (2015) E. Tonsing-Carter et al. MOLECULAR CANCER THERAPEUTICS
- The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
- (2015) J. Canon et al. MOLECULAR CANCER THERAPEUTICS
- Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity
- (2015) YEE-LIN VOON et al. ONCOLOGY REPORTS
- Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma
- (2015) Doris Phelps et al. PEDIATRIC BLOOD & CANCER
- How cell death shapes cancer
- (2015) V Labi et al. Cell Death & Disease
- Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells
- (2015) Bing Z. Carter et al. Oncotarget
- The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
- (2015) Christophe Deben et al. Oncotarget
- Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
- (2015) Lindi Chen et al. Oncotarget
- A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097
- (2015) Sébastien Jeay et al. eLife
- WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma
- (2015) Mark Richter et al. PLoS One
- Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors
- (2015) Asfar S. Azmi et al. Oncotarget
- Evaluation of Zinc (II) chelators for inhibiting p53-mediated apoptosis
- (2015) Akinori Morita et al. Oncotarget
- MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
- (2015) Anne Y. Saiki et al. Oncotarget
- SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression
- (2014) S. Wang et al. CANCER RESEARCH
- Inhibition of miR-17 and miR-20a by Oridonin Triggers Apoptosis and Reverses Chemoresistance by Derepressing BIM-S
- (2014) H. Weng et al. CANCER RESEARCH
- Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation
- (2014) Ramiro París et al. CELL CYCLE
- Obinutuzumab
- (2014) Anne-Laure Gagez et al. CURRENT OPINION IN ONCOLOGY
- Cisplatin in cancer therapy: Molecular mechanisms of action
- (2014) Shaloam Dasari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Could valproic acid be an effective anticancer agent? The evidence so far
- (2014) Seth A Brodie et al. Expert Review of Anticancer Therapy
- Genotoxic Anti-Cancer Agents and Their Relationship to DNA Damage, Mitosis, and Checkpoint Adaptation in Proliferating Cancer Cells
- (2014) Lucy Swift et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development
- (2014) Daqing Sun et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment
- (2014) Yujun Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
- (2014) X Niu et al. LEUKEMIA
- Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia
- (2014) Ingvild Haaland et al. Molecular Cancer
- V-ATPase Inhibition Regulates Anoikis Resistance and Metastasis of Cancer Cells
- (2014) C. M. Schempp et al. MOLECULAR CANCER THERAPEUTICS
- Transient Activation of p53 in G2 Phase Is Sufficient to Induce Senescence
- (2014) Lenno Krenning et al. MOLECULAR CELL
- Drugging the p53 pathway: understanding the route to clinical efficacy
- (2014) Kian Hoe Khoo et al. NATURE REVIEWS DRUG DISCOVERY
- In Vitro Selection of Mutant HDM2 Resistant to Nutlin Inhibition
- (2014) Siau Jia Wei et al. PLoS One
- Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737
- (2014) Dongmin Gu et al. PLoS One
- Targeting PI3K/Akt/mTOR Signaling in Cancer
- (2014) Camillo Porta et al. Frontiers in Oncology
- Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
- (2013) A Meijer et al. BRITISH JOURNAL OF CANCER
- A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis
- (2013) M Kracikova et al. CELL DEATH AND DIFFERENTIATION
- Discontinued drugs in 2012: oncology drugs
- (2013) Robert Williams EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
- (2013) Qingjie Ding et al. JOURNAL OF MEDICINAL CHEMISTRY
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
- (2013) Georgia Hatzivassiliou et al. NATURE
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Protein kinase C and cancer: what we know and what we do not
- (2013) R Garg et al. ONCOGENE
- Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy
- (2013) KATHLEEN I. PISHAS et al. ONCOLOGY REPORTS
- Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation
- (2013) LAURA ASTOLFI et al. ONCOLOGY REPORTS
- Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
- (2013) Monica Franciosi et al. PLoS One
- Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
- (2013) Binh Vu et al. ACS Medicinal Chemistry Letters
- Targeting the PI3K-AKT-mTOR signaling network in cancer
- (2013) Khurum H. Khan et al. Chinese Journal of Cancer
- The central valine concept provides an entry in a new class of non peptide inhibitors of the p53–MDM2 interaction
- (2012) Pascal Furet et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The V-ATPase-Inhibitor Archazolid Abrogates Tumor Metastasis via Inhibition of Endocytic Activation of the Rho-GTPase Rac1
- (2012) R. M. Wiedmann et al. CANCER RESEARCH
- p63/p73 in the control of cell cycle and cell death
- (2012) N. Allocati et al. EXPERIMENTAL CELL RESEARCH
- Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity
- (2012) Paul G Richardson et al. Expert Opinion on Drug Metabolism & Toxicology
- The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status
- (2012) G. Zauli et al. HAEMATOLOGICA
- Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death
- (2012) Laura Conradt et al. INTERNATIONAL JOURNAL OF CANCER
- Cancer and Radiation Therapy: Current Advances and Future Directions
- (2012) Rajamanickam Baskar et al. International Journal of Medical Sciences
- MEK'ing the Most of p53 Reactivation Therapy in Melanoma
- (2012) John T. Lee et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab
- (2012) Brittany P. Kay et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Dynamics of targeted cancer therapy
- (2012) Ivana Bozic et al. TRENDS IN MOLECULAR MEDICINE
- Metal Chaperones: A Holistic Approach to the Treatment of Alzheimer’s Disease
- (2012) Paul Anthony Adlard et al. Frontiers in Psychiatry
- HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma
- (2011) R. J. Jones et al. BLOOD
- CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101
- (2011) M. Jak et al. BLOOD
- MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
- (2011) Hege O Ohnstad et al. BMC CANCER
- Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours
- (2011) Y Pan et al. BRITISH JOURNAL OF CANCER
- Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
- (2011) D. Chen et al. CURRENT CANCER DRUG TARGETS
- Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia
- (2011) E McCormack et al. LEUKEMIA
- Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)
- (2011) E Drakos et al. LEUKEMIA
- Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma
- (2011) Rit Vatsyayan et al. MOLECULAR CARCINOGENESIS
- Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
- (2011) M H Aziz et al. ONCOGENE
- Activation of p53 by Nutlin-3a Induces Apoptosis and Cellular Senescence in Human Glioblastoma Multiforme
- (2011) Ruth Villalonga-Planells et al. PLoS One
- Two-phase dynamics of p53 in the DNA damage response
- (2011) X.-P. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
- (2011) M Michaelis et al. Cell Death & Disease
- Targeted cancer therapies
- (2011) Li Yan et al. Chinese Journal of Cancer
- Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
- (2010) A K Arya et al. BRITISH JOURNAL OF CANCER
- MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity
- (2010) Manujendra N. Saha et al. CANCER BIOLOGY & THERAPY
- Blockade of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase and Murine Double Minute Synergistically Induces Apoptosis in Acute Myeloid Leukemia via BH3-Only Proteins Puma and Bim
- (2010) W. Zhang et al. CANCER RESEARCH
- Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway
- (2010) G. Zauli et al. CLINICAL CANCER RESEARCH
- MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function
- (2010) Asfar S. Azmi et al. EUROPEAN JOURNAL OF CANCER
- Coordination between Cell Cycle Progression and Cell Fate Decision by the p53 and E2F1 Pathways in Response to DNA Damage
- (2010) Xiao-Peng Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- The missing Zinc: p53 misfolding and cancer
- (2010) Stewart N. Loh Metallomics
- Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells
- (2010) R Puca et al. ONCOGENE
- p53-based Cancer Therapy
- (2010) D. P. Lane et al. Cold Spring Harbor Perspectives in Biology
- Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML
- (2009) B. Z. Carter et al. BLOOD
- MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53
- (2009) J A Canner et al. BRITISH JOURNAL OF CANCER
- Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib
- (2009) M. G. Ooi et al. CLINICAL CANCER RESEARCH
- Restoration of p53 Pathway by Nutlin-3 Induces Cell Cycle Arrest and Apoptosis in Human Rhabdomyosarcoma Cells
- (2009) M. Miyachi et al. CLINICAL CANCER RESEARCH
- MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma
- (2009) Y. Tabe et al. CLINICAL CANCER RESEARCH
- Pharmacologic p53 Activation Blocks Cell Cycle Progression but Fails to Induce Senescence in Epithelial Cancer Cells
- (2009) B. Huang et al. MOLECULAR CANCER RESEARCH
- The DNA-damage response in human biology and disease
- (2009) Stephen P. Jackson et al. NATURE
- Death receptor signal transducers: nodes of coordination in immune signaling networks
- (2009) Nicholas S Wilson et al. NATURE IMMUNOLOGY
- Cell fate decision mediated by p53 pulses
- (2009) X.-P. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells
- (2008) Pascale Flandrin et al. CELL STRESS & CHAPERONES
- Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
- (2008) R. Z. Orlowski et al. CLINICAL CANCER RESEARCH
- Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)
- (2008) Avi Ashkenazi et al. JOURNAL OF CLINICAL ONCOLOGY
- The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
- (2008) K Kojima et al. LEUKEMIA
- Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells
- (2008) N. Zhu et al. MOLECULAR CANCER THERAPEUTICS
- Recurrent Initiation: A Mechanism for Triggering p53 Pulses in Response to DNA Damage
- (2008) Eric Batchelor et al. MOLECULAR CELL
- Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition
- (2008) S. Shangary et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started